Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dutch study tracks COVID antivirals in High-Risk patients

NCT ID NCT05195060

Knowledge-focused Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed over 1,100 high-risk COVID-19 patients in the Netherlands who received new antiviral drugs or monoclonal antibodies. Researchers collected blood samples and nasal swabs over 90 days to see how the virus and the body's immune response changed during treatment. The goal was to learn which patients benefit most and to watch for new virus variants, not to test a new treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,178 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients that are treated with neutralizing monoclonal SARS-CoV-2 antibodies and with small drug molecules as standard of care for SARS-CoV-2 infection. Patients can receive the intervention in an outpatient setting, ward or ICU. Woman with child bearing potential are included in the study if the treating physician deemed the treatment safe. We will not determine whether or not a a patient receives a treatment as this is the choice of the treating physician.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients that are treated with neutralizing monoclonal SARS-CoV-2 antibodies or with small-molecules for Covid-19 as standard of care. * Patients have to be aged ≥ 18 y. Exclusion Criteria: * No informed consent is provided by the patient or by his/her legal representative * Patients not suitable to fulfil study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • Amsterdam University Medical Centre

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Amsterdam University Medical centre - VUMC

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Leiden universitair medisch centrum

    Leiden, 2333ZA, Netherlands

  • Radboud Universitair Medisch Centrum

    Nijmegen, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.